|
Mar 26
|
Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High
|
|
Mar 26
|
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
|
|
Mar 25
|
Praxis Precision Medicines to Host PRAX-628 Program Update
|
|
Mar 25
|
A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
|
|
Mar 8
|
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
|
|
Mar 7
|
Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates
|
|
Mar 6
|
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
|
|
Mar 5
|
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 5
|
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Feb 13
|
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is definitely on the radar of institutional investors who own 47% of the company
|
|
Feb 2
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 11
|
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
|
|
Jan 10
|
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
|
|
Jan 9
|
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know
|
|
Jan 8
|
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
|
|
Jan 5
|
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?
|
|
Jan 5
|
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
|
|
Nov 30
|
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade
|
|
Nov 28
|
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
|
|
Aug 28
|
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
|